Medication for Cough in Pulmonary Fibrosis
For patients with pulmonary fibrosis and refractory chronic cough, low-dose controlled-release morphine (5 mg twice daily) is the most effective treatment option, reducing objective cough frequency by approximately 40% compared to placebo. 1
Initial Assessment and Management Approach
Before initiating antitussive therapy, evaluate for:
- Disease progression of the underlying ILD (worsening FVC, DLCO, or radiological changes)
- Complications from immunosuppressive treatment (drug side effects, pulmonary infections)
- Common cough triggers following standard acute, subacute, and chronic cough guidelines 2
What NOT to Use
Avoid these medications as they lack evidence of benefit:
- Inhaled corticosteroids for sarcoidosis-associated cough 2
- Proton pump inhibitors for IPF cough when gastroesophageal reflux workup is negative 2
- Azithromycin - showed no benefit in a randomized controlled trial 3
- Inhaled cromolyn sodium (RVT-1601) - failed to demonstrate efficacy 4
- Gefapixant (P2X3 antagonist) - did not significantly reduce cough 5
Evidence-Based Treatment Algorithm
First-Line: Opioid Therapy
Morphine (controlled-release):
- Dosing: 5 mg orally twice daily 1
- Efficacy: Reduces daytime cough frequency from ~22 coughs/hour to ~13 coughs/hour (39% reduction vs placebo)
- Side effects: Nausea (14%), constipation (21%) - manageable with prophylactic laxatives
- Monitoring: Reassess benefits and risks at 1 week, then monthly 2
Alternative opioid - Nalbuphine ER:
- Dosing: Start 27 mg once daily, titrate up to 162 mg twice daily over 16 days 6
- Efficacy: 75% reduction in daytime cough (52.5 percentage points better than placebo)
- Side effects: Nausea, fatigue, constipation, dizziness more common than morphine
- Note: More complex titration schedule may limit practical use
Second-Line: Neuromodulators
When opioids fail or are contraindicated, consider gabapentin following the CHEST unexplained chronic cough guideline recommendations 2. This represents an off-label use with indirect evidence from chronic cough populations.
Adjunctive Therapy
Multimodality speech pathology therapy should be considered alongside pharmacological treatment for refractory cases 2.
Critical Clinical Considerations
Palliative care context: The 2022 ATS/ERS/JRS/ALAT guideline emphasizes that patients with IPF should have access to palliative care for symptom management including cough 7. Opiates are specifically recommended when alternative treatments have failed and cough adversely affects quality of life 2.
Common pitfall: Do not reflexively prescribe PPIs for IPF-associated cough without documented acid reflux, as this lacks evidence and adds unnecessary medication burden 2.
Quality of life impact: Cough in IPF causes quality of life impairment comparable to unexplained chronic cough and predicts disease progression independent of disease severity 2. This justifies aggressive symptom management.
Strength of Evidence
The morphine recommendation is based on the 2024 PACIFY COUGH trial 1, the most recent high-quality randomized controlled trial specifically addressing this question. This supersedes older guideline suggestions that were consensus-based due to lack of evidence at the time 2. The nalbuphine trial 6 from 2023 provides supporting evidence but with a more complex dosing regimen.
The guideline framework 2 supports using opiates for refractory cough in a palliative setting, and the recent morphine trial 1 now provides the specific evidence to implement this recommendation with confidence.